A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
What I actually want to know is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.
Practical detail welcome, however dull — the duller the better.
NicoleRaleigh said:A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
My labs after 12 months on glycaemic control: A1C 5.2%, fasting glucose 82 mg/dL, fasting insulin 9 uIU/mL. My endo says these are "textbook perfect."
For context, my baseline A1C was 7.9% and fasting glucose was 127 mg/dL. The improvement has been dramatic and consistent.
Dr.NateNeph said:My labs after 12 months on glycaemic control: A1C 5.2%, fasting glucose 82 mg/dL, fasting insulin 9 uIU/mL.
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:
HOMA-IR = (fasting insulin × fasting glucose) ÷ 405
My numbers: Baseline HOMA-IR = 5.9 (insulin resistant) → Current = 1.5 (insulin sensitive)
Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemNicoleRaleigh said:A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
This is my experience too, for whatever a second data point is worth. Nothing to add that would improve it.
Clinical perspective, offered as context rather than as advice.
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 40% to 19%. Target is <36%, with <30% being ideal.
Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.